| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/14779072.6.10.1367 |
| P8608 | Fatcat ID | release_jh53ausvtbh4vksey3zhe2tgke |
| P932 | PMC publication ID | 2650232 |
| P698 | PubMed publication ID | 19018690 |
| P5875 | ResearchGate publication ID | 23482793 |
| P50 | author | Mark J. Nijland | Q43153738 |
| P2093 | author name string | Jeffrey S Gilbert | |
| Penny Knoblich | |||
| P2860 | cites work | The risk of maternal ischaemic heart disease after gestational hypertensive disease | Q81352777 |
| Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression | Q81411178 | ||
| Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature | Q81423834 | ||
| Pre-eclampsia | Q81446389 | ||
| Echocardiographic study of cardiac morphological and functional changes before and after parturition in pregnancy-induced hypertension | Q82763899 | ||
| AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration | Q24290268 | ||
| Soluble endoglin contributes to the pathogenesis of preeclampsia | Q28244053 | ||
| Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia | Q28244090 | ||
| Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia | Q29615916 | ||
| Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor | Q33848380 | ||
| Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study | Q33947553 | ||
| Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy | Q34182166 | ||
| Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. | Q34514153 | ||
| Vitamins C and E and the risks of preeclampsia and perinatal complications | Q34518082 | ||
| Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia | Q34656275 | ||
| Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis | Q34708320 | ||
| Nutrient involvement in preeclampsia | Q35121229 | ||
| Insulin resistance and its potential role in pregnancy-induced hypertension | Q35146337 | ||
| Angiotensin II induces soluble fms-Like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy | Q35699115 | ||
| Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice | Q35701236 | ||
| Hypoxia and sFlt-1 in preeclampsia: the "chicken-and-egg" question | Q35920602 | ||
| Role of the renin-angiotensin system in the pathogenesis of preeclampsia | Q36064478 | ||
| Preeclampsia: a renal perspective | Q36120940 | ||
| Prepregnancy cardiovascular risk factors as predictors of pre-eclampsia: population based cohort study | Q36128984 | ||
| Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia | Q36288766 | ||
| Manifestations of chronic disease during pregnancy | Q36333187 | ||
| C-reactive protein is elevated 30 years after eclamptic pregnancy | Q36681260 | ||
| Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction | Q37022723 | ||
| Preeclampsia and future cardiovascular risk: formal risk factor or failed stress test? | Q37172647 | ||
| Clinical and biochemical evidence of endothelial cell dysfunction in the pregnancy syndrome preeclampsia | Q37421465 | ||
| Role of reactive oxygen species in hypertension produced by reduced uterine perfusion in pregnant rats | Q37449704 | ||
| Relative glucose tolerance and subsequent development of hypertension in pregnancy | Q39569207 | ||
| Vascular endothelial growth factor-mediated induction of manganese superoxide dismutase occurs through redox-dependent regulation of forkhead and IkappaB/NF-kappaB. | Q40526010 | ||
| Endoglin regulates nitric oxide-dependent vasodilatation | Q40597391 | ||
| Glucose intolerance as a predictor of hypertension in pregnancy | Q41030613 | ||
| Placental cytokines and the pathogenesis of preeclampsia | Q41452017 | ||
| Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician's Rosetta Stone | Q41518239 | ||
| CD105 prevents apoptosis in hypoxic endothelial cells | Q42441203 | ||
| Association of maternal endothelial dysfunction with preeclampsia | Q43553727 | ||
| Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia | Q43739445 | ||
| Vascular endothelial growth factor induces manganese-superoxide dismutase expression in endothelial cells by a Rac1-regulated NADPH oxidase-dependent mechanism | Q43771298 | ||
| Role of cardiac eNOS expression during pregnancy in the coupling of myocardial oxygen consumption to cardiac work | Q44103966 | ||
| Insulin, insulin-like growth factor-1, and insulin resistance in women with pregnancy-induced hypertension | Q44141451 | ||
| Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells | Q44320558 | ||
| Agonistic autoantibodies directed against the angiotensin II AT1 receptor in patients with preeclampsia | Q44413491 | ||
| L-arginine attenuates hypertension in pregnant rats with reduced uterine perfusion pressure | Q44760481 | ||
| Maternal-placental interactions of oxidative stress and antioxidants in preeclampsia | Q45112360 | ||
| Renal denervation abolishes hypertension in low-birth-weight offspring from pregnant rats with reduced uterine perfusion | Q45256380 | ||
| Preeclampsia and the risk of end-stage renal disease | Q45748808 | ||
| Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. | Q46339760 | ||
| A rat model of preeclampsia | Q46342948 | ||
| Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion | Q46344658 | ||
| Discovery of a spontaneous genetic mouse model of preeclampsia | Q46351794 | ||
| Maternal and fetal modulators of lipid metabolism correlate with the development of preeclampsia | Q46359043 | ||
| Circulating factors as markers and mediators of endothelial cell dysfunction in preeclampsia | Q46433836 | ||
| Statin treatment in hypercholesterolemic pregnant mice reduces cardiovascular risk factors in their offspring | Q46744956 | ||
| Chronic tempol prevents hypertension, proteinuria, and poor feto-placental outcomes in BPH/5 mouse model of preeclampsia | Q46765356 | ||
| Uterine vascular function in a transgenic preeclampsia rat model | Q46808246 | ||
| Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness | Q46841539 | ||
| Circulating angiogenic factors and the risk of preeclampsia | Q47217679 | ||
| Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women | Q47770771 | ||
| Amniotic vascular endothelial growth factor (VEGF) and nitric oxide (NO) in women with subsequent preeclampsia | Q47907082 | ||
| Insulin resistance and alterations in angiogenesis: additive insults that may lead to preeclampsia | Q47945074 | ||
| Systemic hemodynamic and regional blood flow changes in response to chronic reductions in uterine perfusion pressure in pregnant rats. | Q50952787 | ||
| Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? | Q51033306 | ||
| Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. | Q51037240 | ||
| Effects of reduced uterine perfusion pressure on blood pressure and metabolic factors in pregnant rats. | Q51470693 | ||
| Dyslipoproteinaemia in postmenopausal women with a history of eclampsia. | Q51555876 | ||
| The relationship between abnormal glucose tolerance and hypertensive disorders of pregnancy in healthy nulliparous women. Calcium for Preeclampsia Prevention (CPEP) Study Group. | Q51567295 | ||
| Lipoprotein subfraction changes in normal pregnancy: threshold effect of plasma triglyceride on appearance of small, dense low density lipoprotein. | Q51574204 | ||
| Hyperinsulinemia in glucose-tolerant women with preeclampsia. A controlled study. | Q51581108 | ||
| Fatty acid pattern of esterified and free fatty acids in sera of women with normal and pre‐eclamptic pregnancy | Q51587356 | ||
| Gender-specific effect of overexpression of sFlt-1 in pregnant mice on fetal programming of blood pressure in the offspring later in life. | Q51734953 | ||
| Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. | Q51914188 | ||
| Short- and long-term changes in plasma inflammatory markers associated with preeclampsia. | Q52087250 | ||
| Relation between circulating angiotensin II type 1 receptor agonistic autoantibodies and soluble fms-like tyrosine kinase 1 in the pathogenesis of preeclampsia. | Q52933863 | ||
| Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. | Q53600812 | ||
| First trimester insulin resistance and subsequent preeclampsia: a prospective study. | Q53974694 | ||
| Maternal central hemodynamics in hypertensive disorders of pregnancy. | Q54071183 | ||
| Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic: role of nitric oxide. | Q54130783 | ||
| Soluble fms-Like Tyrosine Kinase 1 Is Increased in Preeclampsia But Not in Normotensive Pregnancies with Small-for-Gestational-Age Neonates: Relationship to Circulating Placental Growth Factor | Q56619503 | ||
| First Trimester Placental Growth Factor and Soluble Fms-Like Tyrosine Kinase 1 and Risk for Preeclampsia | Q56619507 | ||
| Agonistic Angiotensin II Type 1 Receptor Autoantibodies in Postpartum Women With a History of Preeclampsia | Q56981931 | ||
| Relationship of systemic hemodynamics, left ventricular structure and function, and plasma natriuretic peptide concentrations during pregnancy complicated by preeclampsia | Q57009878 | ||
| Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1 | Q57105968 | ||
| Amniotic fluid–soluble vascular endothelial growth factor receptor-1 in preeclampsia | Q57382238 | ||
| Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia | Q64377002 | ||
| The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice | Q64377179 | ||
| National High Blood Pressure Education Program Working Group Report on High Blood Pressure in Pregnancy | Q67266101 | ||
| Catechol-o-methyl transferase activity in the human term placenta | Q68283508 | ||
| Central hemodynamic observations in untreated preeclamptic patients | Q70178496 | ||
| Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR | Q71530460 | ||
| Serum lipoproteins, insulin, and urinary prostanoid metabolites in normal and hypertensive pregnant women | Q72560656 | ||
| Placental insufficiency leads to development of hypertension in growth-restricted offspring | Q73094626 | ||
| Left ventricular function impairment in pregnancy-induced hypertension | Q73699361 | ||
| Renin-angiotensin-aldosterone system in pregnancy-induced hypertension | Q73896725 | ||
| Plasma lipids and vascular dysfunction in preeclampsia | Q74757931 | ||
| Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences | Q79260245 | ||
| Severe feto-placental abnormalities precede the onset of hypertension and proteinuria in a mouse model of preeclampsia | Q80222982 | ||
| Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies | Q80379702 | ||
| P433 | issue | 10 | |
| P921 | main subject | maternal health | Q6786626 |
| circulatory system | Q11068 | ||
| pre-eclampsia | Q61335 | ||
| P304 | page(s) | 1367-1377 | |
| P577 | publication date | 2008-11-01 | |
| P1433 | published in | Expert Review of Cardiovascular Therapy | Q15733727 |
| P1476 | title | Placental ischemia and cardiovascular dysfunction in preeclampsia and beyond: making the connections | |
| P478 | volume | 6 |
| Q57489041 | Assessment of Correlation Between miR-210 Expression and Pre-Eclampsia Risk: A Meta-Analysis |
| Q39555926 | Decreased Cyr61 under hypoxia induces extravillous trophoblasts apoptosis and preeclampsia |
| Q35835560 | Does transthyretin function as one of contributors for preeclampsia? |
| Q35930887 | Expression Profile of MicroRNAs and mRNAs in Human Placentas From Pregnancies Complicated by Preeclampsia and Preterm Labor |
| Q35007417 | FOXO1 expression in villous trophoblast of preeclampsia and fetal growth restriction placentas |
| Q39223093 | From apelin to exercise: emerging therapies for management of hypertension in pregnancy |
| Q38058276 | Genetic association studies in pre-eclampsia: systematic meta-analyses and field synopsis |
| Q33666756 | Maternal and Cord Blood Plasma sEng and TGF-β1 in Patients with Hypertensive Disorders of Pregnancy: A Pilot Study in a South Indian Population |
| Q37694642 | New conception for the development of hypertension in preeclampsia |
| Q37483999 | Placental ischemia and breast cancer risk after preeclampsia: tying the knot |
| Q38115211 | Proteomic approaches to evaluate protein S-nitrosylation in disease. |
| Q33666742 | Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension |
| Q33441799 | Reducing stillbirths: prevention and management of medical disorders and infections during pregnancy |
| Q27004355 | Role of the sympathetic autonomic nervous system in hypoxic remodeling of the fetal cerebral vasculature |
| Q37629960 | Spectrum of Factors Triggering Endothelial Dysfunction in PIH. |
Search more.